Abacus Global Management heads into its August 6 earnings report with short sellers firmly entrenched and options traders turning more defensive than they have been in months.
The options signal is the sharpest near-term read. The put/call ratio has climbed to 0.45, more than two standard deviations above its 20-day average of 0.38 — a defensive posture that stands out given how call-heavy this stock has historically been. That shift has come quickly: through mid-July the PCR was running comfortably in the 0.33–0.39 range before jumping at the end of the month. Short interest reinforces the cautious lean. Bears hold 5.65% of the free float — a meaningful level — though the position has been quietly unwinding, down roughly 6% over the past month from a peak near 5.9M shares in late June. The borrow market offers no real friction: cost to borrow has eased to 0.76%, down 16% on the week and 25% over the past month, while availability is running at 120%, meaning there is roughly 1.2 shares available for every share already borrowed. Bears face no squeeze pressure; the lending pool remains comfortable.
The bull and bear debate on ABX is essentially a growth-versus-execution argument. Bulls point to a projected 60% jump in adjusted net income for 2025, with guidance of $70–78 million, alongside what the company frames as structural demand for its life-insurance monetization business during periods of market volatility. The stock's P/E near 9.5x and EV/EBITDA around 8.2x keep valuation from being an obvious obstacle. Bears counter that revenue growth in the Active Management and Asset Management segments has been inconsistent, U.S.-only exposure leaves the company vulnerable to domestic regulatory and macro shocks, and margin pressure from rising competition in alternative asset management is a genuine risk. The sole analyst covering the name — Piper Sandler, which raised its target to $13 from $10 in July while keeping a Neutral rating — captures the ambivalence: the target implies roughly 20% upside from current levels, but the rating signals the Street isn't yet ready to pound the table.
Insider activity adds a note of caution that is hard to dismiss. The 90-day net position shows $3.6 million in net selling across multiple executives, including the CFO, the Chairman/CEO, and the co-founders. Most recently, CFO Bill McCauley sold nearly $778,000 worth of shares on July 3 at $11.86 — above where the stock trades today at $10.86. The stock has lost 8.4% over the past month despite recovering 2.5% on the week, so sellers above $11 have been proven right so far. The ORTEX short score of 75.9 places ABX in the top percentile for bearish signal intensity, consistent with the elevated SI and the insider pattern, though the score has been remarkably stable for weeks, suggesting the pressure is persistent rather than escalating.
The print will test whether ABX's net income growth story can withstand investor scrutiny after a month of price weakness — and whether the 20% gap between the current price and the lone analyst target reflects genuine upside or simply a valuation anchor that the company has yet to grow into.
See the live data behind this article on ORTEX.
Open ABX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
